VenaSeal Misconceptions: "It Can't Be Used in Women of Childbearing Age" — Where That Claim Comes From, and Why It Is Wrong

With varicose vein treatment more widely discussed than ever, VenaSeal is searched for a great deal — and alongside the information, a particular claim circulates in forums and comment threads:

"VenaSeal can't be used in women of childbearing age." "If there's any chance of pregnancy, you can't have VenaSeal."

To state the conclusion first: this is not correct. Below is where the misunderstanding appears to have come from, and why it does not hold up.

What VenaSeal is

VenaSeal is a vein closure system developed by Medtronic that uses a cyanoacrylate medical adhesive to seal a refluxing saphenous vein from the inside. It received FDA premarket approval in 2015 (PMA P140018), and in Korea it is covered by national health insurance and widely performed.

Unlike heat-based treatments — laser and radiofrequency ablation — it uses no heat, so tumescent anaesthesia is not required, and there is no need for compression stockings afterwards. Short procedure time and quick return to daily activity are the main reasons patients choose it.

Where the misunderstanding comes from

Two separate facts seem to have been blended together.

First, there is a general principle that elective vein procedures are deferred during pregnancy. This applies to every vein treatment — laser, radiofrequency, sclerotherapy — not to VenaSeal in particular. Veins are more dilated during pregnancy and often improve after delivery, so there is little reason to intervene. "During pregnancy" appears to have been stretched, somewhere along the way, into "of childbearing age."

Second, sclerosants used in sclerotherapy — polidocanol among them — are formally contraindicated in pregnancy, because a sclerosant is a drug that reacts chemically inside the vein and can be absorbed. That contraindication is sometimes transferred, wrongly, to the cyanoacrylate used in VenaSeal.

Reason 1: cyanoacrylate acts locally

The cyanoacrylate adhesive polymerises and sets the moment it contacts blood inside the vein. Because it solidifies on contact, it is extremely unlikely to enter the systemic circulation or reach other organs. It is not a dissolved drug absorbed into the bloodstream, as a sclerosant is.

In the clinical studies — the VeClose trial and its five-year extension, the Asian real-world evaluation — no serious adverse event attributable to systemic toxicity has been reported. The adverse events that are seen are local inflammatory reactions around the treated vein, discussed below.

Reason 2: the FDA indication contains no restriction by sex or fertility

The FDA approval states the indication as the permanent closure of lower-extremity superficial truncal veins, such as the great saphenous vein, through endovascular embolisation with coaptation, in adults with clinically symptomatic venous reflux. Nowhere does it exclude women who may become pregnant.

Pregnancy itself is handled the same way as for other elective vein procedures: deferred on clinical judgement. "During pregnancy" and "of childbearing age" are entirely different things. That is the heart of the matter.

Reason 3: the pivotal trials enrolled women, with no sex-based safety signal

The VeClose trial (Morrison et al., Journal of Vascular Surgery, 2015) randomised 222 patients with symptomatic great saphenous vein incompetence to cyanoacrylate closure or radiofrequency ablation. At three months, closure rates were 99% and 96% respectively; procedural pain was similar (2.2 vs 2.4 on a 10-point scale), and there was less bruising at day 3 after cyanoacrylate. Sex was not an exclusion criterion, and no sex-related difference in adverse events was reported.

The five-year extension (Morrison et al., JVS: Venous and Lymphatic Disorders, 2020) followed 89 patients: freedom from recanalisation was 91.4% after cyanoacrylate and 85.2% after radiofrequency, and no long-term device- or procedure-related serious adverse events occurred in either group between three and five years.

The Asian prospective multicentre evaluation (Tang et al., JVS: Venous and Lymphatic Disorders, 2021) treated 100 patients — 59 of them women, mean age 60 — with 100% technical success, 99.3% great saphenous occlusion at three months, and transient superficial phlebitis in 18% of legs that resolved on its own. The safety profile was consistent with the Western trials.

None of this would be possible if the treatment excluded women.

Reason 4: the people who most often need treatment are women of childbearing age

Varicose veins are more common in women, particularly after pregnancy, because of the effects of pregnancy and hormonal change. A large share of patients are women in their thirties to fifties. If VenaSeal were contraindicated in women of childbearing age, it would be contraindicated in one of the largest groups who need treatment — a contradiction with the basic epidemiology of the condition.

Reason 5: confusion with sclerotherapy

Polidocanol and sodium tetradecyl sulphate are pharmacologically active agents, and because an effect on the fetus via the placenta cannot be entirely excluded, they are formally contraindicated during pregnancy. This has led some people to generalise: "vein procedures are risky for women who could become pregnant." But cyanoacrylate is not a pharmacologically active agent. It is a mechanical occluding agent, and its mode of action is fundamentally different.

It is worth adding what the sclerotherapy literature itself says. A 2012 review in Vasa (Reich-Schupke et al.) of sclerotherapy performed in undetected pregnancy found, in the existing case reports and series, no increased risk to mother or child — and concluded that there is no reason to consider termination after such an event. Even the drug that is contraindicated has not been shown to cause harm. The contraindication is precautionary.

What the real precautions are

The considerations that genuinely apply to VenaSeal are these.

During pregnancy, the procedure is deferred. This applies to all elective vein procedures, and the natural course of pregnancy-related vein dilation is observed first.

Cyanoacrylate allergy. Anyone with a history of hypersensitivity to dental adhesives, medical glues or similar should tell the treating doctor before the procedure.

The CHAIR phenomenon — complex hypersensitivity and irritation reaction around the treated vein — has been reported at rates ranging from 0.3% to 25.4% (Joh & Joo, Vascular Specialist International, 2023). Most cases are mild — itching or redness that resolves without treatment — but some recur and need anti-inflammatories, antihistamines or corticosteroids, and surgical excision has rarely been required. No proven way to prevent it has been established.

Beyond these, there is no medical basis for treating "childbearing age" as a contraindication to VenaSeal.

In closing

Medical information should rest on evidence. The claim that VenaSeal cannot be used in women of childbearing age comes from stretching a pregnancy-deferral principle beyond its meaning, or from confusing the adhesive with a sclerosant. The chemistry of cyanoacrylate, the FDA approval and the trial data all point the same way.

Women considering treatment for varicose veins should not lose the opportunity for an appropriate procedure on the strength of a misunderstanding. Whether and when to treat is a decision to make with a vascular specialist, on the basis of your own veins.

---

References

• Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015;61(4):985-94. (PMID: 25650040)
• Morrison N, Gibson K, Vasquez M, et al. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2020;8(6):978-989. (PMID: 32205125)
• Tang TY, Yap CJQ, Chan SL, et al. Early results of an Asian prospective multicenter VenaSeal real-world postmarket evaluation to investigate the efficacy and safety of cyanoacrylate endovenous ablation for varicose veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):335-345.e2. (PMID: 32387378)
• Joh JH, Joo SH. Complex Hypersensitivity and Irritation Reaction (CHAIR) Phenomenon after Cyanoacrylate Closure of Varicose Vein. Vasc Specialist Int. 2023;39:27. (PMID: 37748929)
• Reich-Schupke S, Leiste A, Moritz R, Altmeyer P, Stücker M. Sclerotherapy in an undetected pregnancy — a catastrophe? Vasa. 2012;41(4):243-7. (PMID: 22825857)
• U.S. Food and Drug Administration. VenaSeal Closure System — Premarket Approval P140018. Approved 20 February 2015.